1. An Autism-Linked Mutation Disables Phosphorylation Control of UBE3A
- Author
-
Klaus M. Hahn, William D. Snider, Jason J. Yi, Janet Berrios, Benjamin D. Philpot, Mark J. Zylka, and Jason M. Newbern
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Dendritic spine ,Dendritic Spines ,Ubiquitin-Protein Ligases ,Mutation, Missense ,Biology ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,Neurodevelopmental disorder ,Angelman syndrome ,Enzyme Stability ,medicine ,UBE3A ,Missense mutation ,Animals ,Humans ,Autistic Disorder ,Phosphorylation ,Protein kinase A ,Mutation ,Biochemistry, Genetics and Molecular Biology(all) ,Brain ,medicine.disease ,Embryo, Mammalian ,Molecular biology ,Cyclic AMP-Dependent Protein Kinases ,Mice, Inbred C57BL ,Mutagenesis ,Female ,Angelman Syndrome - Abstract
SummaryDeletion of UBE3A causes the neurodevelopmental disorder Angelman syndrome (AS), while duplication or triplication of UBE3A is linked to autism. These genetic findings suggest that the ubiquitin ligase activity of UBE3A must be tightly maintained to promote normal brain development. Here, we found that protein kinase A (PKA) phosphorylates UBE3A in a region outside of the catalytic domain at residue T485 and inhibits UBE3A activity toward itself and other substrates. A de novo autism-linked missense mutation disrupts this phosphorylation site, causing enhanced UBE3A activity in vitro, enhanced substrate turnover in patient-derived cells, and excessive dendritic spine development in the brain. Our study identifies PKA as an upstream regulator of UBE3A activity and shows that an autism-linked mutation disrupts this phosphorylation control. Moreover, our findings implicate excessive UBE3A activity and the resulting synaptic dysfunction to autism pathogenesis.
- Full Text
- View/download PDF